EA201992883A1 - АНТИТЕЛА К TrkB - Google Patents

АНТИТЕЛА К TrkB

Info

Publication number
EA201992883A1
EA201992883A1 EA201992883A EA201992883A EA201992883A1 EA 201992883 A1 EA201992883 A1 EA 201992883A1 EA 201992883 A EA201992883 A EA 201992883A EA 201992883 A EA201992883 A EA 201992883A EA 201992883 A1 EA201992883 A1 EA 201992883A1
Authority
EA
Eurasian Patent Office
Prior art keywords
trkb
antibodies
therapeutic
compositions
relates
Prior art date
Application number
EA201992883A
Other languages
English (en)
Inventor
Рольф Херрманн
Ремко Александер Баккер
Зебастиан Бандхольц
Петер Михаэль Бенц
Майкл Дзегелевски
Лоре Флорин
Синтия Хесс Кенни
Сара Лоу
Хольгер Розенброк
Санджая Сингх
Хайко Фридрих Шталь
Сатьядеви Венкатарамани
Владимир Войнов
Хайгуан Сяо
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201992883A1 publication Critical patent/EA201992883A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение относится к новым агонистическим антителам к TrkB и терапевтическим и диагностическим способам и композициям для их применения.
EA201992883A 2017-06-09 2018-06-08 АНТИТЕЛА К TrkB EA201992883A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17175122 2017-06-09
PCT/EP2018/065107 WO2018224630A1 (en) 2017-06-09 2018-06-08 Anti-trkb antibodies

Publications (1)

Publication Number Publication Date
EA201992883A1 true EA201992883A1 (ru) 2020-05-08

Family

ID=59034551

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992883A EA201992883A1 (ru) 2017-06-09 2018-06-08 АНТИТЕЛА К TrkB

Country Status (22)

Country Link
US (3) US10793634B2 (ru)
EP (1) EP3635004A1 (ru)
JP (2) JP7267208B2 (ru)
KR (1) KR20200017421A (ru)
CN (1) CN110719916B (ru)
AR (1) AR112602A1 (ru)
AU (1) AU2018279184A1 (ru)
BR (1) BR112019023742A2 (ru)
CA (1) CA3063965A1 (ru)
CL (1) CL2019003557A1 (ru)
CO (1) CO2019013718A2 (ru)
EA (1) EA201992883A1 (ru)
IL (1) IL271067B2 (ru)
MA (1) MA49257A (ru)
MX (1) MX2019014714A (ru)
MY (1) MY202315A (ru)
PE (1) PE20200173A1 (ru)
PH (1) PH12019502694A1 (ru)
SG (1) SG11201911814UA (ru)
TW (2) TWI808086B (ru)
UA (1) UA127967C2 (ru)
WO (1) WO2018224630A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110691790A (zh) * 2017-06-02 2020-01-14 勃林格殷格翰国际有限公司 抗癌联合治疗
AR123862A1 (es) 2020-10-21 2023-01-18 Boehringer Ingelheim Int Moléculas de unión biespecíficas anti-vegf y anti-trkb para el tratamiento de enfermedades oculares
WO2023125485A1 (en) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited TrkB ANTIBODY AND APPLICATION THEREOF

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
CA2149329C (en) 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
PA8678401A1 (es) * 2005-06-06 2009-05-15 Wyeth Corp Anticuerpos monoclonales anti-trkb y sus usos
EA200970469A1 (ru) 2006-11-09 2010-04-30 АйАрЭм ЭлЭлСи Антитела-агонисты рецептора trkb и их применение
JP2010513461A (ja) 2006-12-20 2010-04-30 ライナット ニューロサイエンス コーポレイション 自己免疫障害を治療するためのＴｒｋＢアゴニスト
WO2009048605A1 (en) 2007-10-11 2009-04-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists
BRPI0817812A2 (pt) * 2007-10-23 2015-04-14 Novartis Ag Uso de anticorpos trkb para o tratamento de distúrbios respiratórios
KR101290503B1 (ko) * 2008-01-17 2013-07-26 아이알엠 엘엘씨 개선된 항-ｔｒｋｂ 항체
DK2252633T3 (da) * 2008-02-04 2013-11-11 Lay Line Genomics Spa Anti-TrkA antistoffer og derivater deraf
EP2318010A4 (en) * 2008-07-28 2014-05-21 Univ Emory TREATMENT OF VARIOUS DISORDERS USING TRKB AGONISTS
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
WO2011103667A1 (en) 2010-02-26 2011-09-01 6452728 Canada Inc. Agonistic antibodies to trkb receptors and uses thereof
CN103108633B (zh) 2010-06-09 2016-01-27 爱默蕾大学 TrkB激动剂及其用途
WO2012027821A1 (en) 2010-09-03 2012-03-08 The Royal Institution For The Advancement Of Learning / Mcgill University A trkc receptor agonist antibody to treat neurodegenerative and motor neuron diseases
GB2491106A (en) 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
JP6868394B2 (ja) 2014-05-16 2021-05-12 ファイザー・インク 二重特異性抗体
AU2016298307A1 (en) 2015-07-28 2018-02-15 Otonomy, Inc. TrkB or TrkC agonist compositions and methods for the treatment of OTIC conditions
AU2016356877A1 (en) 2015-11-17 2018-05-10 Glaxosmithkline Intellectual Property Development Limited Binding agonists for treatment of neurological and other disorders
SG11202002665UA (en) 2017-11-30 2020-04-29 Regeneron Pharma Anti-trkb monoclonal antibodies and methods of use

Also Published As

Publication number Publication date
TW202342100A (zh) 2023-11-01
JP7505084B2 (ja) 2024-06-24
TW201920271A (zh) 2019-06-01
CN110719916B (zh) 2024-05-31
US20200399378A1 (en) 2020-12-24
CL2019003557A1 (es) 2020-05-04
CN110719916A (zh) 2020-01-21
JP7267208B2 (ja) 2023-05-01
US10793634B2 (en) 2020-10-06
UA127967C2 (uk) 2024-02-28
SG11201911814UA (en) 2020-01-30
US20180355046A1 (en) 2018-12-13
KR20200017421A (ko) 2020-02-18
IL271067A (en) 2020-01-30
TWI808086B (zh) 2023-07-11
IL271067B2 (en) 2024-06-01
US11866501B2 (en) 2024-01-09
AR112602A1 (es) 2019-11-20
JP2020522270A (ja) 2020-07-30
MA49257A (fr) 2020-04-15
JP2023093621A (ja) 2023-07-04
AU2018279184A1 (en) 2019-11-21
WO2018224630A1 (en) 2018-12-13
MX2019014714A (es) 2020-02-07
MY202315A (en) 2024-04-23
PE20200173A1 (es) 2020-01-24
IL271067B1 (en) 2024-02-01
CO2019013718A2 (es) 2020-01-17
PH12019502694A1 (en) 2020-07-13
EP3635004A1 (en) 2020-04-15
CA3063965A1 (en) 2018-12-13
BR112019023742A2 (pt) 2020-06-09
US20240101689A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
EA201892294A1 (ru) Антитела и композиции против tim-3
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
EA201691541A1 (ru) Новые анти-baff антитела
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
EA201692394A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
EA201892716A1 (ru) Антитела к фактору свертывания xi
EA201891299A1 (ru) Терапевтические антитела к cd9
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
EA201792262A1 (ru) Пироглутамат вортиоксетина
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
EA201992883A1 (ru) АНТИТЕЛА К TrkB
EA201992317A1 (ru) Композиции и способы для диагностики рака легких
EA202191403A1 (ru) Композиция с высокой концентрацией белка